Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | APC | P25054 | 2/20 | 0.40 |
| ▸ | GNPAT | O15228 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662550 | 0.92 | FOLH1 (0.50) | NOD1FOLH1NAALAD2RIMKLAGLO1 | |
| SCHEMBL29516388 | 0.92 | FOLH1 (0.50) | NOD1FOLH1NAALAD2RIMKLAGLO1 | |
| SCHEMBL10646360 | 0.91 | NOD1 (0.49) | NOD1FOLH1GLO1NMT2NMT1 | |
| SCHEMBL10646369 | 0.91 | NOD1 (0.49) | NOD1FOLH1GLO1NMT2NMT1 | |
| SCHEMBL30930160 | 0.91 | NOD1 (0.48) | NOD1FOLH1NAALAD2RIMKLAGLO1 | |
| SCHEMBL29352968 | 0.90 | FOLH1 (0.41) | NOD1FOLH1NAALAD2RIMKLAGLO1 | |
| SCHEMBL31332141 | 0.90 | FOLH1 (0.41) | NOD1FOLH1NAALAD2RIMKLAGLO1 | |
| SCHEMBL30099535 | 0.88 | FOLH1 (0.48) | NOD1FOLH1NAALAD2GLO1MME | |
| SCHEMBL30193512 | 0.88 | FOLH1 (0.51) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL30193388 | 0.88 | FOLH1 (0.51) | NOD1FOLH1NAALAD2RIMKLAGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-114729024-B | Peptide antigens and uses thereof | 博爱米拉索勒股份公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-113993898-B | RET-binding human antibodies and methods of use thereof | 瑞泽恩制药公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-112074298-B | Langerin+Cell targeting | 马克斯·普朗克科学促进协会 | 2025-05-09 | — | — | CN | disclosed |
| CN-112119159-B | Micro-RNA and obesity | 贝斯以色列女执事医疗中心 | 2025-04-29 | — | — | CN | disclosed |
| CN-112740044-B | Method for diagnosis or prognosis of neurological disorders | 阿尔斯特创新有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-114867739-B | Fusion polypeptides comprising GDF15 and a polypeptide domain capable of O-glycosylation | 株式会社LG化学 | 2025-04-08 | — | — | CN | disclosed |
| CN-109722455-B | Method for producing glutacoside by microbial fermentation, engineering bacteria and application | 中国科学院天津工业生物技术研究所 | 2022-03-11 | — | — | CN | disclosed |
| CN-114144527-A | Expression of nitrogenase polypeptides in plant cells | 联邦科学技术研究组织 | 2022-03-04 | — | — | CN | disclosed |
| CN-114127297-A | Genetically reprogrammed CAR-expressing TREG | 加维什-加利里生物应用有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114107322-A | Application of gene for regulating and controlling soluble solid content of tomato fruit | 浙江省农业科学院 | 2022-03-01 | — | — | CN | disclosed |
| CN-108431214-B | Human rotavirus G9P [6] strain and use as vaccine | 美国政府(由卫生和人类服务部的部长所代表) | 2022-03-01 | — | — | CN | disclosed |
| CN-114072677-A | Reagents and methods for cancer detection, prognosis and therapy monitoring | 美国桑福德医疗集团 | 2022-02-18 | — | — | CN | disclosed |
| CN-107208088-B | Oleic acid production in yeast | 银杏生物制品公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-112592912-B | Glycosidase, encoding gene thereof and application thereof | 云南与诺生物工程有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-111849930-B | Mi-2 recombinant antigen and preparation method and application thereof | 珠海丽珠试剂股份有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | NOD1 1292/4885FOLH1 1719/4885NAALAD2 460/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | NOD1 3419/4885FOLH1 305/4885NAALAD2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.